2317P Assessing the cost-effective price-range for pembrolizumab in treating PD-L1–high advanced non-small cell lung cancer (NSCLC) in South Africa.
Saved in:
| Title: | 2317P Assessing the cost-effective price-range for pembrolizumab in treating PD-L1–high advanced non-small cell lung cancer (NSCLC) in South Africa. |
|---|---|
| Authors: | Trapani, D.1 (AUTHOR), Ruff, P.2 (AUTHOR), Cairoli, F.3 (AUTHOR), Burrone, E.4 (AUTHOR), Segafredo, G.4 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1272-S1272. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2933 |
